SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

Clinical trial NCT06538935 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06538935
Sponsor: Fujian Cancer Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma SBRT Immune Checkpoint Blockade Tyrosine Kinase Inhibitor

Start date: 2025-01-01
Primary completion: 2026-12-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.